USA, BioNanomatrix Receives Additional Funds to Commercialize Single-Molecule Analyzer

BioNanomatrix, Inc., a Philadelphia, Pennsylvania-based developer of single-molecule genomic analysis technology, received two new supplemental grants totaling $833,490 from the National Human Genome Research Institute (NHGRI) of the U.S. National Institutes of Health (NIH).
These grants bring the total that BioNanomatrix has been awarded under the Phase II NHGRI grant program to more than $2.8m. They are part of a Small Business Innovation Research (SBIR) program, awarded under the NIH BECON II nanotech initiative, an interdisciplinary, multi-institutes consortium.
The funds will be used to support further commercial development of BioNanomatrix’s nanoscale whole genome imaging and analysis platform. BioNanomatrix plans to use the funds to prepare for the upcoming beta site launch of its first commercial NanoAnalyzer system, planned for the second quarter of 2010.


Join the discussion